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we retrospectively evaluated 272 (169 M,
103 F) consecutive children that between
June 1985 and January 2001 underwent
BMT at the "G. Gaslini" Institute. Subjects
with solid tumor were excluded. Their
median age at transplant was 8 years
(range 2 mos. - I 9 yr.), and the source
of stem cells was autologous (A), related
donor (RD)., and unrelated donor (UD)
in 87, 115 and 70 subjects, respectively.
166 children received total body irradiation
(TBI) as part of the conditioning regimen;
63 received Busulfan while 43 were
treated with other drugs; finally, 54 chil-
dren received cranial prophylactic
irradiation (CPI) (1800 cGy) during front
line treatment before BMT.
A total of 41 SNE were observed
in 37 children (18 M, 19 F); their median
age at BMT was 10 years (range 2 - 16 yr.).
Neurological symptoms occurred after
a median time of 92 days (range 5 - 3203)
The source of HSCT was UD-BM, RD-BM,
and A-BM in 19, 16, and 2 cases respe-
ctively.). Ten of them received CPI before
BMT. Neurological symptoms were: seizu-
res (n=20), changes of mental status
and coma (n=12), motor or sensitive
defects (n=6), progressive loss of cogni-
tive functions (n=3), clonus and myoclonus
(n=2) and visual impairment (n=1). Causes
of neurological symptoms were attributed
to CSA toxicity (CSA-t) in 21 pt. (77%),
to irradiation or chemotherapy injury (IC-i)
in 7 (2.6%), to CNS infections (CNS-I)
in 7 (2.6%), to CNS hemorrhages in 3 pt.
(1.1 %) and to immunomediated
pathogenesis in the remaining 3 (1.1 %).
CSA-t occurred in 21 out of 185 patients
receiving immunosuppressive therapy.
Onset of symptoms was after a median
of 96 days (range 20 - 370 days) after
BMT. When CSA was discontinued, a com-
plete resolution of SNE was observed in all
cases. The 7 IC-i occurred between
1 month and 7 years after BMT. Mental
deterioration and lor coma were observed
in 5, clonus and dysarthria in one and
visual impairment in another. CNS-I were
observed in 7 pt. and were mostly of viral
origin (2 cases of EBV, and 1 of CMV,
HHV6 and adenovirus, respectively),
whereas the 2 remaining cases had
neurotoxoplasmosis and aspergillosis.
The 3 CNS hemorrhages occurred 30, 50
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and 250 days from BMT, respectively.
Finally the 3 immunomedia-ted SNE were
due to a demyelinating leucoencephalo-
pathy in the context of ex-tensive chronic
GvHD in2 cases; and to a Guillain-Barre
syndrome in the remainning one.
Preliminary analysis shows that type
of BMT (p<0.01) and TBI (p<0.05) are risk
factors for SNE; gender, age at BMT,
and CPI were not associated with
an increased risk of SNE. Risk factors
for the 5 different types of. SNE will
be presented and discussed.
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Late onset steroid-resistant idiopathic
thrombocytopenic purpura (ITP) after
allogeneic transplant remains rare yet
important clinical problem. Two cases
of ITP late post transplant are reported
and discussed.
Patient UPN 176. 16-year old girl with
MDS-RA underwent allogeneic PBSCT
from male matched unrelated donor
in August 2000. She was conditioned with
Bu 16mg/kg, Cy 200 mg/kg and ATG
20 mg/kg. GvHD prophylaxis consisted
of CsA, MTX and methylprednisolone
(MP). Hematological recovery was
adequate: ANC > 0.5 Gil on day +16,
platelets> 50 Gil on day +33. Mild aGvHD
1° resolved quickly. No complications were
observed until January 2001 (147 days
after transplantation), when she developed
ITP with a platelet count of 7 Gil and
numerous petechiae. BM biopsy confirmed
trilineage engratfment with almost 100%
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donor chimaerism. Megakaryocytes were
abundant and appeared normal. Analysis
of lymphocyte subsets revealed rapid
recovery of CD19+ B cells (131/1-'1, inc!.
CD5+CD19+ cells) in comparison with the
previous examination a month ago (9/1-'1)
and substantial number of CD3+CD4+ Th
cells (> 100/1-'1). Steroid-treatment was
ineffective and she received high-dose
(HD) IVIG (2g/kg over 4 days) with
sustained curative effect. She remains
now in CR of both MDS and ITP with
100% donor chimaerism (XY-FISH).
Patient UPN 142. 10-month-old boy with
Omenn Syndrome underwent allogeneic
haploidentical T-cell depleted (TCD)
PBSCT from HLA-mismatched mother
in October 1999. He was conditioned with
Bu 20mg/kg, TT 10mg/kg, Flu 200mg/m2
and OKT-3. GvHD prophylaxis consisted
of TCD (CliniMACS®), CsA, MP and MMF.
Hematological recovery was prompt: ANC
> 0.5 GIl on day +9, platelets > 50 GIl
on day +30. Neither GvHD nor other
serious complications were observed until
May 2000 (217 days after transplantation),
when he developed ITP. with a platelet
count of 31 GIL Chimaerism analysis
confirmed 100% donor engraftment.
Immune studies revealed rapid recovery
of CD19+ B cells (324/1-'1, incl.
CD5+CD19+ cells) in comparison with
the previous examination two months ago
(57/1-'1) and peripheral expansion
of CD3+CD4+ cells (> 400/1-'1) incl.
CD4+CD69+ cells. Different modalities
for treatment of ITP were tried with
transient success. Prednisone (4mg/kg)
together with IVIG (OAg/kg) resulted in ITP
resolution lasting 2 months. Platelet count
dropped again to 51 G/l in August 2000
and HD IVIG (2g/kg) was administered
with good yet transient effect. Four more
HD IVIG courses every month were
required to attain final ITP resolution
in January 2001 - 14 months post
transplant. The child remains now alive
and well with platelet count above 200 GIL
Conclusions. Rapid B cell recovery
correlates with the occurrence of late
onset steroid-resistant ITP in recipients
of alternative transplants. Th (CD3+CD4+)
cell recovery might also trigger
autoimmunity by IL-2 mediated non-
specific immune activation. The treatment
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of choice remains HD IVIG. Anti-D
immunoglobulin might be used in Rh-
positive patients. A novel highly effective
option might be therapy with chimeric
monoclonal anti-CD 20 antibody (rituximab
- Mabthera®).
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Wilms' tumour (WT) is the most common
primary genitourinary tumour of childhood
with the annual incidence of approximately
8 per million children younger than
15 years of age. Genetic plays an impor-
tant role in this cancer. WT1 located
on chromosome 11 p13, WT2 on 11 p15,
loci at 1p, 7p, 16q, 17p (the p53 tumor
suppressor gene), and 19q (the putative
familial WT gene FWT2) are believed
to harbor genes involved in the biology
of WT. The majority of these children are
surviving into adult life and due to the
combination of genetic susceptibility,
irradiation and antineoplastic treatment,
are at increased risk for second malignant
neoplasms (SMNs). We report the case
of a young man with a parotid carcinoma
occurring thirteen years after diagnosis
of WT. The patient was initially treated
according to the SlOP 6 Nephroblastoma
protocol, comprising a 4-week two-drug
(Actinomycin 0, Vincristine) presurgical
treatment, nephrectomy and 22-week
treatment with biweekly Actinomycin 0
and Vincristine. No radiation therapy was
given. Nine months after the end of the-
rapy he experienced an isolated hepatic
relapse, treated with Peptichemio
(450 mg/m2), two courses of Cisplatin
(40 mg/m2/day for 5 days) and Etoposide
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